Valuation: OraSure Technologies, Inc.

Market Cap 273M 243M 227M 207M 390M 26.29B 393M 2.74B 1.06B 13.44B 1.03B 1B 43.13B P/E 2026 *
-6.01x
P/E 2027 * -4.9x
Enterprise Value 273M 243M 227M 207M 390M 26.29B 393M 2.74B 1.06B 13.44B 1.03B 1B 43.13B EV / Sales 2026 *
2.24x
EV / Sales 2027 * 2.05x
Free-Float
93.52%
Yield 2026 *
-
Yield 2027 * -
1 day+2.19%
1 week+0.89%
Current month+1.15%
1 month+9.83%
3 months-8.85%
6 months+28.73%
Current year+63.84%
1 week 3.76
Extreme 3.76
4.02
1 month 3.14
Extreme 3.145
4.12
Current year 2.33
Extreme 2.33
4.58
1 year 2.08
Extreme 2.08
4.58
3 years 2.08
Extreme 2.08
8.45
5 years 2.08
Extreme 2.08
11.59
10 years 2.08
Extreme 2.08
23.01
Manager TitleAgeSince
Chief Executive Officer 52 03/06/2022
Director of Finance/CFO 54 07/08/2022
Chief Tech/Sci/R&D Officer - 30/11/2024
Director TitleAgeSince
Director/Board Member 59 31/05/2020
Director/Board Member 66 07/11/2021
Director/Board Member 52 03/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
29/09/26 Free

Director

4,797 0.0070%
06/09/26 Tax

Chairman

-5,116 0.0074%
03/06/26 Free

Director

46,106 0.0670%
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%+0.89%+26.68%-32.91% 273M
+0.84%-3.74%-26.69%+1.85% 169B
-0.07%-2.55%-9.53%+11.07% 110B
+0.90%+1.13%-24.83%+0.58% 106B
-1.24%-0.76%-49.04%-12.75% 73.87B
-0.24%+0.69%+0.16%+72.58% 58.98B
-0.86%+2.96%+13.57%+59.50% 51.28B
-0.71%-3.82%-7.72%-31.41% 48.16B
+0.12%-0.17%-18.21%+20.29% 40.84B
-1.01%-1.45%+28.48%-9.72% 32.21B
Average -0.01%-0.90%-6.71%+7.91% 69.05B
Weighted average by Cap. +0.03%-1.30%-16.35%+10.11%

Financials

2026 *2027 *
Net sales 122M 108M 101M 92.3M 174M 11.74B 176M 1.23B 475M 6B 458M 449M 19.26B 133M 118M 110M 101M 190M 12.81B 192M 1.34B 518M 6.55B 500M 489M 21.01B
Net income -46.2M -41.05M -38.31M -34.92M -65.86M -4.44B -66.47M -464M -180M -2.27B -173M -170M -7.29B -57.65M -51.23M -47.81M -43.58M -82.19M -5.54B -82.95M -579M -224M -2.83B -216M -212M -9.09B
Net Debt - -
Logo OraSure Technologies, Inc.
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
Employees
500
Date Price Change Volume
02/10/26 US$3.965 +2.19% 420,751
01/10/26 US$3.880 -1.02% 480,869
30/09/26 US$3.920 +2.62% 837,478
29/09/26 US$3.820 -3.29% 538,113
28/09/26 US$3.950 +0.51% 848,229
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.965USD
Average target price
4.000USD
Spread / Average Target
+0.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OSUR Stock